Literature DB >> 26822829

Epithelial-mesenchymal transition: a new target in anticancer drug discovery.

Fabrizio Marcucci1, Giorgio Stassi2, Ruggero De Maria3.   

Abstract

The conversion of cells with an epithelial phenotype into cells with a mesenchymal phenotype, referred to as epithelial-mesenchymal transition, is a critical process for embryonic development that also occurs in adult life, particularly during tumour progression. Tumour cells undergoing epithelial-mesenchymal transition acquire the capacity to disarm the body's antitumour defences, resist apoptosis and anticancer drugs, disseminate throughout the organism, and act as a reservoir that replenishes and expands the tumour cell population. Epithelial-mesenchymal transition is therefore becoming a target of prime interest for anticancer therapy. Here, we discuss the screening and classification of compounds that affect epithelial-mesenchymal transition, highlight some compounds of particular interest, and address issues related to their clinical application.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26822829     DOI: 10.1038/nrd.2015.13

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  203 in total

Review 1.  Regulatory networks defining EMT during cancer initiation and progression.

Authors:  Bram De Craene; Geert Berx
Journal:  Nat Rev Cancer       Date:  2013-02       Impact factor: 60.716

2.  Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness.

Authors:  Elisa Giannoni; Francesca Bianchini; Lorenzo Masieri; Sergio Serni; Eugenio Torre; Lido Calorini; Paola Chiarugi
Journal:  Cancer Res       Date:  2010-08-10       Impact factor: 12.701

3.  Selective targeting of radiation-resistant tumor-initiating cells.

Authors:  Mei Zhang; Rachel L Atkinson; Jeffrey M Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-03       Impact factor: 11.205

4.  Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis.

Authors:  Bing Cui; Suping Zhang; Liguang Chen; Jianqiang Yu; George F Widhopf; Jessie-F Fecteau; Laura Z Rassenti; Thomas J Kipps
Journal:  Cancer Res       Date:  2013-06-15       Impact factor: 12.701

5.  NF-kappaB-dependent plasticity of the epithelial to mesenchymal transition induced by Von Hippel-Lindau inactivation in renal cell carcinomas.

Authors:  Allan J Pantuck; Jiabin An; Huiren Liu; Matthew B Rettig
Journal:  Cancer Res       Date:  2010-01-12       Impact factor: 12.701

6.  TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells.

Authors:  M Bartucci; R Dattilo; C Moriconi; A Pagliuca; M Mottolese; G Federici; A Di Benedetto; M Todaro; G Stassi; F Sperati; M I Amabile; E Pilozzi; M Patrizii; M Biffoni; M Maugeri-Saccà; S Piccolo; R De Maria
Journal:  Oncogene       Date:  2014-02-17       Impact factor: 9.867

7.  Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma.

Authors:  Longyi Zheng; Wen Yang; Fuquan Wu; Chao Wang; Lexing Yu; Liang Tang; Bijun Qiu; Yuqiong Li; Linna Guo; Mengchao Wu; Gensheng Feng; Dajin Zou; Hongyang Wang
Journal:  Clin Cancer Res       Date:  2013-08-13       Impact factor: 12.531

8.  Matrix rigidity regulates a switch between TGF-β1-induced apoptosis and epithelial-mesenchymal transition.

Authors:  Jennifer L Leight; Michele A Wozniak; Sophia Chen; Michelle L Lynch; Christopher S Chen
Journal:  Mol Biol Cell       Date:  2012-01-11       Impact factor: 4.138

9.  A cell-based small molecule screening method for identifying inhibitors of epithelial-mesenchymal transition in carcinoma.

Authors:  Kian-Ngiap Chua; Wen-Jing Sim; Victor Racine; Shi-Yun Lee; Boon Cher Goh; Jean Paul Thiery
Journal:  PLoS One       Date:  2012-03-14       Impact factor: 3.240

10.  Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance.

Authors:  Kari R Fischer; Anna Durrans; Sharrell Lee; Jianting Sheng; Fuhai Li; Stephen T C Wong; Hyejin Choi; Tina El Rayes; Seongho Ryu; Juliane Troeger; Robert F Schwabe; Linda T Vahdat; Nasser K Altorki; Vivek Mittal; Dingcheng Gao
Journal:  Nature       Date:  2015-11-11       Impact factor: 49.962

View more
  124 in total

Review 1.  Roles of Grainyhead-like transcription factors in cancer.

Authors:  S M Frisch; J C Farris; P M Pifer
Journal:  Oncogene       Date:  2017-07-17       Impact factor: 9.867

2.  From "high" ZEB1 to "low" B-cell lymphoma 2-interacting mediator of cell death (BIM)-an epithelial-mesenchymal transition (EMT)-associated drug resistance pathway elucidated.

Authors:  Fabrizio Marcucci; Cristiano Rumio
Journal:  J Thorac Dis       Date:  2019-01       Impact factor: 2.895

Review 3.  New knowledge of the mechanisms of sorafenib resistance in liver cancer.

Authors:  Yan-Jing Zhu; Bo Zheng; Hong-Yang Wang; Lei Chen
Journal:  Acta Pharmacol Sin       Date:  2017-03-27       Impact factor: 6.150

4.  Association between periostin and epithelial-mesenchymal transition in esophageal squamous cell carcinoma and its clinical significance.

Authors:  Ya-Jing Lv; Wei Wang; Chu-Shu Ji; Ming-Ran Xie; Bing Hu
Journal:  Oncol Lett       Date:  2017-05-05       Impact factor: 2.967

Review 5.  How do cancer cells replenish their fuel supply?

Authors:  Abdallah K Alameddine; Frederick T Conlin; Brian J Binnall; Yvonne A Alameddine; Khaled O Alameddine
Journal:  Cancer Rep (Hoboken)       Date:  2018-04-30

6.  Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing.

Authors:  Charissa Kim; Ruli Gao; Emi Sei; Rachel Brandt; Johan Hartman; Thomas Hatschek; Nicola Crosetto; Theodoros Foukakis; Nicholas E Navin
Journal:  Cell       Date:  2018-04-19       Impact factor: 41.582

Review 7.  Applications of tumor chip technology.

Authors:  Stephanie J Hachey; Christopher C W Hughes
Journal:  Lab Chip       Date:  2018-09-26       Impact factor: 6.799

8.  Honokiol inhibits EMT-mediated motility and migration of human non-small cell lung cancer cells in vitro by targeting c-FLIP.

Authors:  Xiao-Qin Lv; Xin-Ran Qiao; Ling Su; Shu-Zhen Chen
Journal:  Acta Pharmacol Sin       Date:  2016-09-05       Impact factor: 6.150

Review 9.  Naturally occurring compounds acting as potent anti-metastatic agents and their suppressing effects on Hedgehog and WNT/β-catenin signalling pathways.

Authors:  L Farahmand; B Darvishi; K Majidzadeh-A; A Madjid Ansari
Journal:  Cell Prolif       Date:  2016-09-27       Impact factor: 6.831

Review 10.  Overcoming chemoresistance by targeting reprogrammed metabolism: the Achilles' heel of pancreatic ductal adenocarcinoma.

Authors:  Abudureyimu Tuerhong; Jin Xu; Si Shi; Zhen Tan; Qingcai Meng; Jie Hua; Jiang Liu; Bo Zhang; Wei Wang; Xianjun Yu; Chen Liang
Journal:  Cell Mol Life Sci       Date:  2021-06-15       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.